相似文献
1
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.
J Med Chem. 2005 Dec 29;48(26):8103-7. doi: 10.1021/jm050726b.
2
Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury.
J Thorac Cardiovasc Surg. 2010 Aug;140(2):440-6. doi: 10.1016/j.jtcvs.2010.03.002. Epub 2010 Apr 15.
3
Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.
Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H1183-9. doi: 10.1152/ajpheart.00264.2011. Epub 2011 Jul 8.
4
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
J Med Chem. 2005 Mar 24;48(6):1745-58. doi: 10.1021/jm049580r.
5
Design and in Vivo Characterization of A Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.
J Med Chem. 2019 Feb 14;62(3):1502-1522. doi: 10.1021/acs.jmedchem.8b01662. Epub 2019 Jan 3.
6
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.
Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9. doi: 10.1016/j.bmcl.2008.04.001. Epub 2008 Apr 4.
7
Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.
Purinergic Signal. 2015 Sep;11(3):389-407. doi: 10.1007/s11302-015-9460-9. Epub 2015 Jul 1.
8
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.
J Med Chem. 2012 May 24;55(10):4847-60. doi: 10.1021/jm300396n. Epub 2012 May 16.
9
Design, synthesis, and biological activity of N6-substituted-4'-thioadenosines at the human A3 adenosine receptor.
Bioorg Med Chem. 2006 Jul 15;14(14):4718-30. doi: 10.1016/j.bmc.2006.03.030. Epub 2006 Apr 5.
10
Nucleotide P2Y receptor agonists are in vitro and in vivo prodrugs of A/A adenosine receptor agonists: implications for roles of P2Y and A/A receptors in physiology and pathology.
Purinergic Signal. 2020 Dec;16(4):543-559. doi: 10.1007/s11302-020-09732-z. Epub 2020 Oct 31.
引用本文的文献
1
Potent and Selective Human 5-HT Serotonin Receptor Antagonists: 4'-Cyano-(N)-methanocarba-adenosines by Synthetic Serendipity.
J Med Chem. 2024 Dec 12;67(23):21264-21291. doi: 10.1021/acs.jmedchem.4c02174. Epub 2024 Nov 26.
2
Structure activity relationships of 5-HT and 5-HT serotonin receptor antagonists: N, C2 and 5'-Modified (N)-methanocarba-adenosine derivatives.
Eur J Med Chem. 2023 Nov 5;259:115691. doi: 10.1016/j.ejmech.2023.115691. Epub 2023 Jul 31.
3
Machine Learning for Discovery of New ADORA Modulators.
Front Pharmacol. 2022 Jun 22;13:920643. doi: 10.3389/fphar.2022.920643. eCollection 2022.
4
Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.
RSC Med Chem. 2021 Jul 13;12(11):1808-1825. doi: 10.1039/d1md00167a. eCollection 2021 Nov 17.
5
NUCLEOSIDE PRODRUGS OF A ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS.
Collect Czechoslov Chem Commun. 2006;71(6):912-928. doi: 10.1135/cccc20060912.
6
Role of Adenosine and Purinergic Receptors in Myocardial Infarction: Focus on Different Signal Transduction Pathways.
Biomedicines. 2021 Feb 18;9(2):204. doi: 10.3390/biomedicines9020204.
7
Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development.
Front Cell Neurosci. 2019 Mar 28;13:124. doi: 10.3389/fncel.2019.00124. eCollection 2019.
8
Design and in Vivo Characterization of A Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series.
J Med Chem. 2019 Feb 14;62(3):1502-1522. doi: 10.1021/acs.jmedchem.8b01662. Epub 2019 Jan 3.
9
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A adenosine receptor antagonists.
Medchemcomm. 2018 Oct 18;9(11):1920-1932. doi: 10.1039/c8md00317c. eCollection 2018 Nov 1.
10
A Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.
Med Res Rev. 2018 Jul;38(4):1031-1072. doi: 10.1002/med.21456. Epub 2017 Jul 6.
本文引用的文献
1
Adenosine and brain function.
Int Rev Neurobiol. 2005;63:191-270. doi: 10.1016/S0074-7742(05)63007-3.
2
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.
J Med Chem. 2005 Mar 24;48(6):1745-58. doi: 10.1021/jm049580r.
3
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
J Med Chem. 2005 Mar 10;48(5):1550-62. doi: 10.1021/jm049408n.
4
Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury.
Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2792-801. doi: 10.1152/ajpheart.01157.2004. Epub 2005 Jan 28.
5
A new synthetic route to (North)-methanocarba nucleosides designed as A3 adenosine receptor agonists.
J Org Chem. 2005 Jan 21;70(2):439-47. doi: 10.1021/jo0487606.
6
Navigating chemical space for biology and medicine.
Nature. 2004 Dec 16;432(7019):855-61. doi: 10.1038/nature03193.
7
Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.
Bioorg Med Chem. 2004 May 1;12(9):2021-34. doi: 10.1016/j.bmc.2004.02.037.
8
Adenosine receptor agonists: from basic medicinal chemistry to clinical development.
Expert Opin Emerg Drugs. 2003 Nov;8(2):537-76. doi: 10.1517/14728214.8.2.537.
9
Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency.
Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1070-5. doi: 10.1152/ajpheart.00940.2003. Epub 2003 Nov 26.
10
Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury.
Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2780-7. doi: 10.1152/ajpheart.00411.2003. Epub 2003 Aug 14.
Zotero 插件